Clinical Guidelines for Maternal Cardiac Imaging

Abstract

Cardiac disease in pregnancy is a leading cause of maternal morbidity and mortality globally. Accurate and timely diagnosis through appropriate cardiac imaging is vital, but presents unique challenges due to physiological adaptations in pregnancy and concerns regarding fetal safety. This review synthesizes current clinical guidelines, recent research, and practical strategies for cardiac imaging in pregnant patients, focusing on evidence-based modality selection, risk mitigation, and multidisciplinary care. The article aims to provide clinicians with a comprehensive framework to optimize maternal and fetal outcomes through judicious imaging choices aligned with contemporary standards.

Introduction

Cardiovascular disorders complicate an increasing number of pregnancies, driven by advanced maternal age, rising prevalence of congenital heart disease survivors, and comorbidities such as hypertension and diabetes. The evaluation of suspected or known cardiac disease during pregnancy demands a nuanced approach, balancing diagnostic yield with maternal and fetal safety. Clinical guidelines emphasize targeted imaging tailored to the clinical scenario, highlighting the importance of modality selection, timing, and multidisciplinary coordination. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, and current recommendations for cardiac imaging in pregnancy, integrating recent advances and guideline-based management strategies.

Epidemiology / Disease Burden

Cardiac disease accounts for up to 15% of maternal deaths in developed nations, with incidence rates rising in parallel with maternal age and comorbidities. Congenital heart disease, rheumatic heart disease, cardiomyopathies, and acquired valvular lesions are prominent contributors. The global burden is further compounded by disparities in access to cardiac care and imaging, notably in low- and middle-income regions. Timely diagnosis is often hindered by overlapping symptoms with normal pregnancy, underscoring the critical need for standardized imaging protocols and awareness among providers.

Pathophysiology

Pregnancy induces profound cardiovascular changes, including a 30–50% increase in plasma volume, elevated cardiac output, reduced systemic vascular resistance, and hemodilution. These adaptations can unmask latent cardiac pathology or exacerbate established disease. For example, increased preload and decreased afterload may precipitate decompensation in women with valvular stenosis or myocardial dysfunction. Understanding these physiological shifts is essential for interpreting imaging findings accurately and differentiating pathological changes from normal gestational adaptations.

Risk Factors

Major risk factors for adverse cardiac events in pregnancy include pre-existing structural or functional cardiac disease, poorly controlled hypertension, diabetes mellitus, advanced maternal age, obesity, and family history of sudden cardiac death. Other predictors include prior cardiac events, left ventricular dysfunction, cyanosis, pulmonary hypertension, and the presence of mechanical heart valves. Recognizing these factors is essential for risk stratification and early referral for specialized cardiac imaging and multidisciplinary care.

Clinical Features

Presenting features of cardiac disease in pregnancy may be subtle or nonspecific, frequently overlapping with common gestational symptoms. Palpitations, exertional dyspnea, syncope, chest pain, orthopnea, and peripheral edema warrant thorough evaluation. Signs such as new or changing murmurs, jugular venous distension, rales, cyanosis, or arrhythmias should prompt urgent cardiac assessment. A high index of suspicion and systematic use of validated risk scores guide the need for advanced imaging beyond initial clinical assessment and basic echocardiography.

Diagnosis

Diagnostic imaging is pivotal for characterizing structural, functional, and hemodynamic abnormalities. Transthoracic echocardiography (TTE) is the cornerstone modality due to its safety profile, portability, and ability to assess chamber size, function, valve integrity, and pulmonary pressures without ionizing radiation. Transesophageal echocardiography (TEE) may be indicated for better resolution in selected cases. Cardiac magnetic resonance imaging (CMR) offers superior tissue characterization and volumetric analysis without radiation, suitable for complex congenital disease or cardiomyopathies, though gadolinium use is generally avoided. Computed tomography (CT) and nuclear imaging are reserved for situations where benefits clearly outweigh fetal risks, with dose minimization protocols strictly enforced. Electrocardiography (ECG) and chest X-ray remain valuable adjuncts; appropriate abdominal shielding is mandatory when X-ray is necessary.

Treatment & Management

Management is multidisciplinary, integrating imaging findings with clinical status to guide therapy. Medical management may include beta-blockers, diuretics, anticoagulation, or antiarrhythmic drugs, tailored to maternal and fetal safety profiles. Invasive procedures, including catheter-based interventions or surgery, require careful timing and risk stratification, often guided by serial imaging. Delivery planning is coordinated with obstetricians, anesthesiologists, and neonatologists, emphasizing the role of imaging in monitoring hemodynamic status peri- and postpartum.

Recent Advances / Emerging Therapies

Technological advances have refined maternal cardiac imaging. Speckle-tracking echocardiography enables sensitive detection of subclinical myocardial dysfunction. Three-dimensional echocardiography enhances anatomic detail, aiding surgical planning. Low-dose CT protocols and novel CMR sequences reduce fetal exposure while providing high-fidelity data. Artificial intelligence-driven image analysis is emerging for automated quantification and risk prediction. Guidelines are evolving to incorporate these modalities, with ongoing research into their utility and safety in pregnancy.

Guideline Recommendations

Current consensus from the American Heart Association (AHA), European Society of Cardiology (ESC), and relevant obstetric organizations advocates for echocardiography as the first-line imaging modality in most scenarios. CMR is recommended for complex cases or when echocardiography is inconclusive, provided gadolinium is avoided unless absolutely indicated. CT and nuclear imaging are discouraged unless critical for maternal management. Imaging protocols must minimize fetal exposure, employ shielding, and use the lowest feasible radiation dose. Multidisciplinary collaboration and individualized care plans are paramount, with shared decision-making that considers maternal and fetal risks and benefits.

Conclusion

The safe and effective use of cardiac imaging in pregnancy is a cornerstone of modern maternal care. Adherence to evidence-based guidelines, judicious modality selection, and a team-based approach enable early diagnosis, optimal risk stratification, and tailored management of cardiac disease in pregnancy. Ongoing advancements in imaging technology and research continue to refine clinical practice, with the ultimate goal of improving outcomes for both mother and child.